SEARCH:   Advanced

Blood, 1 January 2005, Vol. 105, No. 1, pp. 397-404. Prepublished online as a Blood First Edition Paper on April 29, 2004; DOI 10.1182/blood-2004-01-0298. This Article Full Text (PDF) All Versions of this Article: 2004-01-0298v1 105/1/397    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Milligan, D. W Articles by Catovsky, D. Search for Related Content PubMed PubMed Citation Articles by Milligan, D. W Articles by Catovsky, D. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 30, 2004 Accepted April 7, 2004 Autografting for younger patients with chronic lymphocytic leukaemia is safe and achieves a high percentage of molecular responses. Results of the MRC Pilot Study Donald W Milligan*, Savio Fernandes, Ranjit Dasgupta, Faith E Davies, Estella Matutes, Christopher D Fegan, Christopher McConkey, J A Child, David Cunningham, Gareth J Morgan, and Daniel Catovsky Haematology, Birmingham Heartlands Hospital, Birmingham, United Kingdom Haematology, Leeds General Infirmary, Leeds, United Kingdom Haematology, Royal Marsden Hospital, London, United Kingdom CRUK Institute for Cancer Studies, University of Birmingham, Birmingham, United Kingdom * Corresponding author; email: d.w.milligan{at}bham.ac.uk. We have assessed autologous stem cell transplantation after treatment with fludarabine, in previously untreated patients with CLL. This study is the first to enrol previously untreated patients and follow them prospectively. The initial response rate to fludarabine was 82% (94/115). Stem cell mobilisation was attempted in 88 patients and was successful in 67% (59/88). Overall 56% (65/115) of patients entered into the study proceeded to autologous transplant. The early transplant related mortality was 1.5% (1/65). The number of patients in complete remission after transplant increased from 37% (24/65) to 74% (48/65), and 26/41 (63%) patients who were not in complete remission at the time of their transplant achieved a complete remission post transplant. The five-year overall and disease-free survival from transplantation was 77.5% (CI 57.2, 97.8%) and 51.5% (CI 33.2, 69.8%) respectively. None of the variables examined at study entry were found to be predictors of either overall or disease-free survival. 16 of 20 evaluable patients achieved a molecular remission on a polymerase chain reaction (PCR) for immunoglobulin heavy chain gene re-arrangements in the first six months following their transplant. Detectable molecular disease by PCR was highly predictive of disease recurrence. It is of concern that 5/65 (8%) patients developed post-transplant AML/MDS. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. G. Gribben The Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 291 - 296. [Abstract] [Full Text] [PDF] K. W. L. Yee and S. M. O'Brien Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2006; 81(8): 1105 - 1129. [Abstract] [Full Text] [PDF] C. Moreno, N. Villamor, D. Colomer, J. Esteve, E. Gine, A. Muntanola, E. Campo, F. Bosch, and E. Montserrat Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia Blood, June 1, 2006; 107(11): 4563 - 4569. [Abstract] [Full Text] [PDF] J. Delgado, K. Thomson, N. Russell, J. Ewing, W. Stewart, G. Cook, S. Devereux, R. Lovell, R. Chopra, D. I. Marks, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study Blood, February 15, 2006; 107(4): 1724 - 1730. [Abstract] [Full Text] [PDF] B. L. Abbott Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment Oncologist, January 1, 2006; 11(1): 21 - 30. [Abstract] [Full Text] [PDF] J. G. Gribben, D. Zahrieh, K. Stephans, L. Bartlett-Pandite, E. P. Alyea, D. C. Fisher, A. S. Freedman, P. Mauch, R. Schlossman, L. V. Sequist, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia Blood, December 15, 2005; 106(13): 4389 - 4396. [Abstract] [Full Text] [PDF] M. L. Sorror, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. J. Stuart, U. Hegenbart, E. Agura, T. R. Chauncey, J. Leis, M. Pulsipher, et al. Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia J. Clin. Oncol., June 1, 2005; 23(16): 3819 - 3829. [Abstract] [Full Text] [PDF] J. G. Gribben Salvage Therapy for CLL and the Role of Stem Cell Transplantation Hematology, January 1, 2005; 2005(1): 292 - 298. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020